RMC No. 81-2021 identifies FDA-listed VAT-exempt medicines, COVID-19 drugs, vaccines, and medical devices under CREATE, with key dates.

Businesses selling or importing qualifying medicines, COVID-19 treatment drugs and vaccines, and COVID-19 medical devices must treat covered items as VAT-exempt based on the FDA-endorsed list of VAT-exempt products under the CREATE Act. The practical effect is immediate for invoicing, importation, pricing, tax mapping, and VAT return preparation: covered products should not be subjected to 12% VAT for the applicable periods, while non-covered products remain subject to the ordinary VAT rules.

What RMC No. 81-2021 Changed

RMC No. 81-2021 publishes the FDA-endorsed List of VAT-Exempt Products pursuant to Republic Act No. 11534, otherwise known as the Corporate Recovery and Tax Incentives for Enterprises Act or CREATE Act. For businesses, the key change is not merely administrative. The circular identifies the operative reference list for determining which products may be sold or imported without VAT under the expanded VAT exemption rules for certain medicines, drugs, vaccines, and medical devices.

The circular states that the FDA letter was dated June 17, 2021 and that the attached List of VAT-Exempt Products consists of fifty-eight pages. This matters because taxpayers cannot simply rely on a generic description such as medicine, vaccine, or medical device. The safer compliance approach is to match the actual product being sold or imported against the FDA-endorsed list and the applicable product category and period.

Products Covered by the VAT Exemption

The VAT exemption applies to the sale or importation of specifically covered products falling under the categories stated in RMC No. 81-2021. The first category covers medicines for diabetes, high cholesterol, and hypertension. The second category covers medicines for cancer, mental illness, tuberculosis, and kidney diseases. The third category covers drugs and vaccines prescribed and directly used for COVID-19 treatment. The fourth category covers medical devices directly used for COVID-19 treatment.

For tax managers and accountants, the important point is that the exemption is product-specific and category-specific. A company selling pharmaceutical products, medical supplies, or healthcare-related inventory should not assume that all items in the same commercial line are VAT-exempt. The relevant compliance question is whether the product falls within the FDA-endorsed List of VAT-Exempt Products and within the applicable effective period stated in RMC No. 81-2021.

Effective Dates and Deadlines Businesses Must Apply

RMC No. 81-2021 states different effective dates depending on the product category. Medicines for diabetes, high cholesterol, and hypertension are VAT-exempt beginning January 1, 2020. Medicines for cancer, mental illness, tuberculosis, and kidney diseases are VAT-exempt beginning January 1, 2021.

For COVID-19-related products, the exemption is time-bound. Drugs and vaccines prescribed and directly used for COVID-19 treatment are VAT-exempt beginning January 1, 2021 until December 31, 2023. Medical devices directly used for COVID-19 treatment are also VAT-exempt beginning January 1, 2021 until December 31, 2023.

These dates are especially important for taxpayers reviewing sales invoices, import entries, VAT declarations, and accounting records covering 2020, 2021, 2022, and 2023. A product that qualifies under the diabetes, high cholesterol, and hypertension category may have VAT treatment beginning January 1, 2020, while COVID-19 treatment drugs, vaccines, and medical devices have a stated end date of December 31, 2023 under the circular.

Who Is Most Affected

RMC No. 81-2021 is most relevant to pharmaceutical companies, drug distributors, importers of medicines, hospitals, clinics, pharmacies, medical device distributors, healthcare procurement teams, and companies involved in the sale or importation of COVID-19 treatment products. It is also important for corporate accountants, CFOs, tax compliance officers, customs brokers, and in-house counsel who review VAT treatment, import documents, and supplier invoices.

SMEs in the pharmacy, clinic, medical supply, and distribution space should pay particular attention because the financial impact of VAT treatment can be significant. A 12% VAT charge on a covered VAT-exempt product may affect pricing, customer billing, input tax reporting, and contractual pricing arrangements. Large corporations and hospital groups should likewise review enterprise resource planning tax codes, product masters, and procurement classifications to prevent inconsistent VAT treatment across branches, warehouses, or affiliates.

Key Compliance Requirements for Sellers and Importers

Businesses should first identify all products in their inventory, sales catalog, or import pipeline that may fall under the categories covered by RMC No. 81-2021. The relevant search and accounting phrases include VAT-exempt medicines Philippines, CREATE Act VAT exemption medicines, FDA List of VAT-Exempt Products, COVID-19 medical devices VAT exemption, and RMC 81-2021 VAT-exempt products.

Second, each product should be checked against the FDA-endorsed List of VAT-Exempt Products. The product category should then be linked to the correct effective date. This is essential because the effective date for diabetes, high cholesterol, and hypertension medicines begins January 1, 2020, while the effective date for cancer, mental illness, tuberculosis, and kidney disease medicines begins January 1, 2021. COVID-19 treatment drugs, vaccines, and medical devices have the stated period from January 1, 2021 until December 31, 2023.

Third, accounting teams should review invoices and official receipts issued during the applicable periods. Where a covered product was treated as VATable, the company should evaluate the proper accounting and tax reporting treatment based on its specific facts, documentation, and BIR compliance posture. Where a product was treated as VAT-exempt, the business should preserve evidence showing that the product is within the FDA-endorsed list and within the period stated in RMC No. 81-2021.

Penalties and Risk of Non-Compliance

RMC No. 81-2021 does not state a separate penalty schedule. However, incorrect VAT treatment may still create ordinary tax compliance risks under the National Internal Revenue Code and related BIR rules. For sellers, charging VAT on a VAT-exempt product may create invoicing, pricing, customer refund, and tax return issues. For buyers and importers, claiming input VAT on purchases that should have been treated as VAT-exempt may create exposure during tax audit.

The main compliance risk is documentation. If a taxpayer applies VAT exemption without being able to show that the product is covered by the FDA-endorsed list and the correct effective period, the BIR may question the VAT treatment. Conversely, if a taxpayer continues charging VAT on covered products, the business may face commercial disputes with customers and possible tax reporting inconsistencies.

Practical Steps Businesses Should Take Now

Companies should immediately map their medicine, vaccine, and medical device SKUs against the FDA-endorsed List of VAT-Exempt Products and classify them by effective date. Tax teams should coordinate with procurement, importation, pharmacy operations, sales, and billing teams so that the product master file uses the correct VAT codes. This should be done at the SKU level, not merely at the product family or supplier level.

Businesses should also review historical transactions beginning January 1, 2020 for medicines for diabetes, high cholesterol, and hypertension, and beginning January 1, 2021 for the other categories stated in RMC No. 81-2021. For COVID-19 treatment drugs, vaccines, and medical devices, the review should take into account the stated period ending December 31, 2023.

For importers, customs and tax teams should align import documentation with the VAT-exempt classification. For pharmacies, hospitals, clinics, and distributors, front-end billing systems should be reconciled with tax reporting systems to prevent a mismatch between invoices, ledgers, and VAT returns. In-house counsel should also review supply contracts where prices were quoted as VAT-inclusive or VAT-exclusive, because the VAT exemption may affect pricing and contractual allocation of tax costs.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists businesses in reviewing BIR issuances, CREATE Act tax incentives, VAT exemptions, and healthcare-related tax compliance. Our tax and business law team can help determine whether specific products fall within the applicable VAT-exempt categories, review invoices and contracts, and prepare compliance positions for BIR audit or internal tax governance purposes.

For companies selling or importing medicines, COVID-19 treatment products, or medical devices, the safest approach is to document the VAT basis before an audit or customer dispute arises. For assistance with RMC No. 81-2021, VAT-exempt products, and BIR compliance in the Philippines, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *